Proinflammation of Aging Central Arteries: A Mini-Review

Mingyi Wang  Robert E. Monticone  Edward G. Lakatta
Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Biomedical Research Center (BRC), Baltimore, Md., USA

Key Words
Aging · Arterial remodeling · Proinflammation · Cellular phenotype

Abstract
Arterial aging is a cornerstone of organismal aging. The central arterial wall structurally and functionally remodels under chronic proinflammatory stress over a lifetime. The low-grade proinflammation that accompanies advancing age causes arterial wall thickening and stiffening. These structural and functional alterations are consequences of adverse molecular and cellular events, e.g. an increase in local angiotensin II signaling that induces an inflammatory phenotypic shift of endothelial and smooth muscle cells. Thus, interventions to restrict proinflammatory signaling are a rational approach to delay or prevent age-associated adverse arterial remodeling.

Introduction
Aging exponentially increases the morbidity and mortality of quintessential cardiovascular diseases, including hypertension and atherosclerosis, which are closely correlated with intimal-medial thickening and arterial stiffening [1–3]. Studies from animal experiments and human tissue samples demonstrate that age-associated arterial structural and functional changes are the consequence of a proinflammatory phenotypic shift of the arterial cells, including endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and (myo)fibroblasts (tables 1, 2) [2–5]. These cellular alterations are closely associated with chronic activation of the angiotensin II (Ang II) signaling cascade [5]. The molecular and cellular events drive arterial wall elastin fragmentation, fibrosis, calcification, glycation, and amyloidosis with advancing age (fig. 1) [2–5].

Proinflammation in the arterial wall is an autoregulated Ang II signaling phenomenon in response to pathophysiological conditions, facilitating ‘full-blown’ inflammation [5]. This Ang II signaling in the arterial wall with aging originally appears to serve a protective/adaptive biological goal overcoming the changes in hemodynamics and humoral factors, and eventually sets a fertile stage for the initiation and progression of the pathogenesis of hypertension and atherosclerosis in the elderly (fig. 1; table 2) [2, 3, 5]. The existing proinflammation lowers the threshold for ‘battle signaling triggers’ and therefore augments arterial inflammation and increases the incidence of thrombosis, calcification, and lipid pool formation in the advanced arterial lesions with a clinical presentation in the elderly population [1, 6–10]. Thus, suppression of age-associated arterial proinflammation is a rational ap-
Leading proinflammatory vasoactive stressors

Transcription factors and downstream molecules

Phenotypic shift of ECs/VSMCs/fibroblasts

Microscopic arterial aging phenotype shift

Clinical phenotype of arterial aging

Age-associated arterial diseases

**Fig. 1.** Diagram of age-associated proinflammatory arterial remodeling, modified from Wang et al. [2]. Signal Cascades: (i) The chronic proinflammatory profile within central arteries with advancing age is characterized by alterations in signaling systems that include Ang II signaling via its receptor AT1, aldosterone/MR, ET-1/ETA signaling. AGEs recruit inflammatory molecules by interaction with their cellular transduction receptor for AGEs (RAGE). (ii) Proinflammatory transcription factors such as NF-κB and Ets-1 are activated within the aging arterial wall, whereas protective factors such as Nrf2 and SIRT1 are reduced. (iii) Downstream signaling molecules include MFG-E8, MMPs, calpain-1, MCP-1, TGF-β1. Activation of calpain-1, MMPs, TGF-β1, and NADPH oxidase increases whereas NO bioavailability decreases with advancing age. (iv) Differences of AAASP are observed in the cytokine secretion profile of primary VSMCs derived from young and aged non-human primates. Compared to young VSMCs, old cells exhibit secretion of increased amounts of MFG-E8, MCP-1, MMP2 and TGF-β1. Concurrent proinflammatory proliferation, migration, secretion, senescence, and ECM remodeling are characteristic features of ECs, VSMCs, and (myo)fibroblasts within the aged arterial wall. (v) Microscopic arterial aging changes include disruption of the endothelium, intima-media thickening, arterial amyloidosis, fibrosis, elastin fracture, matrix glycoxidative modifications, and calcification that are consequences of the enhanced signaling via these receptor signaling cascades. (vi) There is growing evidence that a significant interaction exists between aging and hypertension/atherosclerosis.

*(For second part of legend see next page.)*
Arterial, Cellular, and Molecular Events with Aging

Age-associated proinflammatory molecular remodeling and signaling alter the phenotype of vascular cells, including ECs, VSMCs, and (myo)fibroblasts, facilitating adverse arterial remodeling with aging (table 2; fig. 1) [2–5].

Intima

The intima, which lies between the luminal surface and the internal elastic lamina of the artery, is a ‘frontline stress field’ for the arterial wall. Age predominantly alters

Table 1. Distribution and cellular sources of inflammation-associated molecules in the old compared to the young central arterial wall.

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Thickened intima</th>
<th>Degenerated media</th>
<th>Expanded adventitia</th>
<th>Cell origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ang II</td>
<td>↑↑</td>
<td>↑</td>
<td>?</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>ACE-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>Chymase</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>Ma, M, NH</td>
</tr>
<tr>
<td>ET-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, Ra</td>
</tr>
<tr>
<td>MFG-E8</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R, H, NH</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, H</td>
</tr>
<tr>
<td>MCP-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, Ra, H, NH</td>
</tr>
<tr>
<td>MMP-2/9</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, H, NH</td>
</tr>
<tr>
<td>Calpain-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R, H</td>
</tr>
<tr>
<td>eNOS</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>iNOS</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R</td>
</tr>
<tr>
<td>PDGF/R</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R</td>
</tr>
<tr>
<td>tPA</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R</td>
</tr>
<tr>
<td>uPA</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R</td>
</tr>
<tr>
<td>PAI-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R</td>
</tr>
<tr>
<td>AGEs</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>PTM, M, R, H, NH</td>
</tr>
<tr>
<td>ICAM</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, NH</td>
</tr>
<tr>
<td>TGF-α3</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>IL-1/6/8</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>AT1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>TβIIIR</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, R, Ra</td>
</tr>
<tr>
<td>MR</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, Ra, H, NH</td>
</tr>
<tr>
<td>Coll I/II/III</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, Ra, H, NH</td>
</tr>
<tr>
<td>NF-κB</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
<tr>
<td>Ets-1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, S</td>
</tr>
<tr>
<td>Nrf2</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, NH</td>
</tr>
<tr>
<td>SIRT1</td>
<td>↑↑</td>
<td>↑</td>
<td>↑</td>
<td>E, S, F, M, R, H, NH</td>
</tr>
</tbody>
</table>

See figure 1 for abbreviations and acronyms. ↑↑ = Predominantly increase; ↑ = increase; ↓ = decrease; ↓↓ = increase or decrease; ? = unknown. E = Endothelial cells; S = vascular smooth muscle cells; F = (myo)fibroblasts; Ma = mast cells; M = mice; R = rats; Ra = rabbits; H = humans; NH = nonhumans; PTM = post-translational modification.
the cellular and molecular quality and quantity of this zone through the Ang II signaling pathway [2–5]. With advancing age, VSMCs infiltrate into the subendothelial space, the modified extracellular matrix (ECM) expands via glyoxylation, and proinflammatory molecules such as Ang II accumulate in the thickened intima, contributing to EC apoptosis and senescence [2–5].

### Endothelial Apoptosis

The actions of Ang II induces increases in TNF-α, calpain-1, MCP-1, ROS, and MFG-E8 and decreases the NO bioavailability and SIRT1 activity, presenting a proinflammatory molecular stress into the endothelia of aged rats, monkeys and humans [2–5]. These molecular signals lead to caspase-3/-9 activation and consequently DNA cleavage, resulting in EC apoptosis, a cellular event of NF-κB activation that has been observed in the old endothelium in vivo and is closely associated with a decline of endothelial-dependent flow-induced dilatation [11–13].

### Endothelial Senescence

Ang II and ROS molecular signals induce telomere shortening or damage endothelial mitochondrial DNA, triggering senescence via an activation of the DNA dam-

---

### Table 2. Molecular and cellular remodeling; modified from Wang et al. [3]

<table>
<thead>
<tr>
<th></th>
<th>Aging</th>
<th>Hyper-tension</th>
<th>Atherosclerosis</th>
<th>Ang II Signaling</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>humans</td>
<td>monkeys</td>
<td>rats</td>
<td>rabbits</td>
</tr>
<tr>
<td></td>
<td>&gt;56 vs. &lt;20 years</td>
<td>15–20 vs.</td>
<td>24–30 vs.</td>
<td>2–6 years vs.</td>
</tr>
<tr>
<td></td>
<td>&lt;20 years</td>
<td>&lt;10 years</td>
<td>3–8 months</td>
<td>&lt;10 months</td>
</tr>
<tr>
<td><strong>Inflammation-association molecules</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local Ang II/AT₁</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>ET-1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>MMPs</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Calpain-1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>MCP-1/CCR2</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>TGF-β₁/β₁IR</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>NADPH oxidase</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>NO bioavailability</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>TNF-α₁</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>MFG-E8</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>PDGF/PDGFR</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>tPA/uPA</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>AGEs/RAGE</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>IL-1/6/-8</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>MR</td>
<td>?</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>NF-κB</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Ets-1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>SIRT1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td><strong>Cellular-matrix structure and function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EC dysfunction</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Diffuse IMT</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Stiffness</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Matrix</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Calcification</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>FN/collagen</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>VSMC migration</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>VSMC proliferation</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td><strong>Related diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension prevalence</td>
<td>↑</td>
<td>–</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Atherosclerosis prevalence</td>
<td>↑</td>
<td>–</td>
<td>–</td>
<td>↑</td>
</tr>
</tbody>
</table>

See figure 1 for abbreviations and acronyms. ↑ = Increase; ↓ = decrease; – = not present; ? = unknown.
age ataxia-telangiectasia-mutated protein (ATM)/CHK2/p53/p21 signaling pathway [14–16]. Importantly, EC senescence within the old arterial wall is accelerated by glycemic conditions [15]. The extent of EC senescence is closely associated with endothelial dysfunction [15–17].

**Media**

The media, a patterned region between the internal and external elastic lamina of central arteries, provides the vessel’s second line of defense. It is composed of a circumferential arrangement of VSMCs, the predominant cell type around the elastic lamina and other ECM such as collagen. The morphology and orientation of aged VSMCs are considerably varied and their behavior is substantially heterogeneous such as proliferation/invasion/ senescence/apoptosis, which is closely associated with proinflammation [18–22]. Importantly, with advancing age, the medial elastin laminae become eroded and fractured, and collagens, in particular collagen types I, III, and IV, are deposited and degraded around VSMCs [23, 24].

**VSMC Senescence and Secretion**

Abundant Ang II is present around or within VSMCs within the old arterial wall. Some aortic VSMCs of 34-month-old rats (old) are polyploid and larger in size than those in the aorta from 3-month-old rats, and are enriched in NADPH oxidase 4 (NOX4) and p16 (INK4a) [19, 20]. Survivin, a chromosome messenger protein, decreases in the majority of such polyploid cells, and a cell-cycle arrest status known as senescence occurs in these cells [19]. These findings suggest that Ang II induces VSMC senescence [25, 26]. Indeed, chronic exposure to Ang II increases DNA damage in VSMCs and induces senescence, which can be substantially reduced by overexpression of human telomerase [26]. This scenario is known as replicative senescence. Furthermore, acute exposure to Ang II is also associated with increased sensing, transducing, and effecting the signaling of DNA damage: p53 acetylation and p21 activation in senescent VSMCs, independent of telomere attrition [26]. Overexpression of human telomerase in this instance does not retard senescence [26]. This scenario is referred to as stress-induced premature senescence (SIPS). In addition, alterations of the ECM may facilitate the senescence of VSMCs induced by Ang II [27]. Indeed, VSMCs isolated from collagenase-resistant collagen type I mutant mouse aorta, a premature aging model, are susceptible to Ang II-induced senescence via upregulation of p16 and p21 [27]. Strikingly, these mutant mice have hypertension and a shortened lifespan [27].

An age-associated arterial secretory phenotype (AAASP) is observed in the cytokine secretion profile of primary VSMCs derived from old non-human primates (fig. 1) [28]. Old cells secrete more interleukin-1β (IL-1β), interleukin-6 (IL-6), MCP-1, and TNF-α, resembling the fibroblast senescence-associated secretory phenotype (SASP) [28]. This proinflammatory profile suggests that senescent or senescent-like events likely occur in the central arterial wall with aging. Emerging evidence indicates that the AAASP likely delivers proinflammatory signals to exaggerate post-injury neointima formation and enhances the arterial calcification shift with aging [29–31].

**VSMC Apoptosis**

Apoptotic VSMCs are seldom detected in the grossly normal aged aortic wall [13, 21]. Growing evidence indicates that isolated VSMCs from old donors are susceptible to the development of apoptosis via increased ROS production or NF-kB activation [21–22]. Apoptotic VSMCs directly promote arterial remodeling via activation of migration, proliferation of neighboring cells and collagen synthesis fueled by inflammatory molecules such as IL-6 [32]. Furthermore, an increased number of apoptotic VSMCs is closely associated with age-associated arterial stiffening and adverse remodeling [22, 32].

**VSMC Proliferation**

Intimal cell hyperplasia is a ‘hallmark’ of arterial aging in rats. Some subsets of old VSMCs enriched in cyclin-dependent kinase 4 (CDK4), proliferative nuclear antigen (PCNA) and Ki-67 have powerful proliferative capacity [33–35]. Old VSMCs are surrounded by and embedded in a ruptured matrix protein barrier that facilities their proliferation [36]. In rats and rabbits, old VSMCs proceed through the cell cycle faster than young cells [33–35]. The replication rate of old cultured VSMCs is increased, compared to those from their young counterparts [33–35]. Compared to young VSMCs, a greater percentage of old cultured VSMCs reside in the S and G2/M phases, and a lower percentage in the G0/G1 phase [33, 35]. In young cultured VSMCs, MFG-E8, a downstream molecule of Ang II signaling, induces phosphorylation of ERK1/2, augments levels of PCNA, CDK4 and PDGF/PDGFR signaling, increases 5-bromo-2-deoxyuridine (BrdU) incorporation, and promotes proliferation via αvβ5 integrin signaling [33]. MFG-E8 silencing, integrin inhibition, or the block-
Ang II signaling, via activation of TGF-β1, is a powerful VSMCs produce and maintain a complex meshwork of molecules and facilitates proliferation in old VSMCs.

In mice, the basal levels of proliferative capacity of old VSMCs are markedly lower than that of young cells, due mainly to an increased production of ROS [37]. Under the PDGF challenged conditions, however, the proliferation rate of old VSMCs is dramatically accelerated compared to that in young cells [38].

Importantly, in humans, the proliferative and embryonic markers such as PCNA and embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) are observed in old aortic intima, which is linked to Ang II signaling [21, 39]. Indeed the proliferative capacity of isolated VSMCs from humans is increased with aging [21, 39].

**VSMC Migration and Invasion**

The migration/invasion of VSMCs from the arterial media to the intima is a key cellular event in the initiation and progression of age-associated diffuse intimal thickening. With advancing passage in culture, the invasive capacity of young VSMCs increases up to that of old cells, via increased activation of gelatinases induced by Ang II signaling [2–4, 39–43]. Old cultured VSMCs in early passage exhibit an exaggerated migration/invasion capacity compared to young VSMCs [39–43]. Exposure of early passage young VSMCs to Ang II, calpain-1, MFG-E8, PDGF-BB, or MCP-1 via activation of MMP-2 enhances their invasive capacity up to those levels observed in untreated old cells [39, 42]. These age-associated VSMC invasive characteristics are blocked by the MMP inhibitor, GM6001; AT1 antagonist, losartan, and calpain-1 inhibitor, calpastatin [39–43]. Furthermore, MFG-E8 silencing RNA substantially reduces MCP-1, PDGF and its receptor expression and consequently reduces VSMC invasion capacity [33, 43].

**VSMC ECM Production**

ECM not only structurally supports the artery, determining its mechanical behavior, but also regulates cellular proinflammatory phenotypes in the arterial wall with aging. Enhanced collagen deposition is a salient feature of ECM remodeling of the aging arterial wall [23, 39, 44–47]. VSMCs produce and maintain a complex meshwork of ECM, including collagen types I, II, and III. Increased Ang II signaling, via activation of TGF-β1, is a powerful profibrogenic factor that governs the production of collagen molecules by VSMCs [44–47]. MMP-2-activated TGF-β1/TβRII signaling is also involved in increased production of collagen I, II, and III, and the biologic glue fibronectin (FN), by old VSMCs [44, 47]. In addition, activation of intracellular calcium-dependent proteinase calpain-1 in old VSMCs, via MMP-2 activation, is involved in TGF-β1 activation and increased collagen production [47].

VSMCs also produce collagen type IV, an element of the basement membrane, proteoglycans, and hyaluronic acid. These matrices become degenerated and accumulate within the arterial wall and function as a reservoir of bioactive factors, PDGF, oxLDL, and MMP-2/-9, which regulate behavior of VSMCs such as proliferation and migration with aging [36, 48–50]. Importantly, these ECMs also modulate the process of calcification and neointima formation [48–51].

**VSMC Stiffness**

Increased aortic stiffness is an important feature of vascular aging. The elastic modulus (stiffness) measured by atomic force microscopy (AFM) of VSMCs isolated from old monkey aortae is increased compared to that of young VSMCs [52]. This increased VSMC stiffness is abolished by disassembling of the actin cytoskeleton with cytochalasin D [52]. Furthermore, VSMC stiffness is also higher in old than in young cells in a reconstituted tissue model [52]. In addition, the adhesion capacity of VSMCs from old arteries measured via AFM is increased versus that from young monkeys [53]. Thus, increased in vivo arterial stiffness with aging is attributable, not only to changes in ECM, but also to intrinsic changes in VSMC stiffness and adhesion capacity.

**Elastin Fragmentation**

Elastin fiber fracture along with the deposition of collagen is a hallmark of age-associated arterial remodeling. The close association of elastin and collagen to VSMCs in the aortic wall causes alterations in viscoelastic characteristics that account for many of its static and dynamic mechanical features. The elastin lamella and the contents of its adjacent interlamellar zone represent the unit of structure and function of the mammalian lamella, and are closely linked to elasticity, which progressively deteriorates with advancing age [23, 45]. Interestingly, recent studies reveal that the age-associated elastin degeneration and disassembly are tightly controlled by Ang II-associated micro-RNA 29 [54, 55]. In addition, a soluble fibrillin-1 bound latent TGF-binding protein is released during destruction of the elastin network and sets the stage for the stepwise activation of TGF-β1 by Ang II signaling MMP-2, which, as noted, regulates collagen production of VSMCs [45, 56].
Adventitia

The adventitia is an outermost layer of loose connective tissue, serving as the artery’s final line of defense, functioning as a biological processing center for the retrieval, integration, storage and release of key regulators of arterial wall function [57]. It is composed of fibroblasts, pericytes, mast cells, and smooth muscle progenitor cells, and bundles of thick collagen, disoriented elastin fibers, vasa vasorum, nerve bundles, and lymphoid organization. Notably, adventitial remodeling is mainly determined by activation of fibroblasts known as myofibroblasts.

(Myofibroblasts

Fibroblasts are predominantly adventitial cells. With advancing age or under proinflammatory conditions, fibroblasts, ECs, and VSMCs are all activated and synthesize α-smooth muscle actin (α-SMA), and become myofibroblasts [58–62]. Exposure of Ang II and Aldo to these cells enhances their inflammation, migration, and proliferation, likely contributing to arterial adverse remodeling and stiffening [63, 64].

Aging Arterial Phenotype

Aortic wall calcification, glyoxycation, and amyloidosis increases with advancing age, and aortic tissue becomes fertile soil for the pathogenesis of hypertension and atherosclerosis (fig. 1).

Calcification

Arterial calcification is a salient component of the age-associated arterial remodeled phenotype. Old cultured VSMCs, phenotypically shifted from contractile to chondro-osseous differentiation, are able to produce large amounts of bone-like substrates, including collagen II in response to inflammatory factors such as calpain-1, and become biomineralized as calcification [47]. Overexpression of calpain-1 reduces the calcification inhibitors, tissue inhibitor type II of MMP-2 (TIMP-2), osteonectin, and osteopontin (OPN), and induces alkaline phosphatase and membrane type I of MMP-2 (MT1-MMP) activity in young VSMCs. This profile when calpain-1 is overexpressed resembles that of old VSMCs [47]. Impressively, calpain-1 activity, MMP-2 activity, and collagen II are upregulated within the human calcified aorta [47].

The activity of tissue transglutaminase (TG2), which catalyzes the cross-linking of proteins, increases in the old arterial wall [65] and is closely regulated by NO bioavail-

DOI: 10.1159/000362548
yaloid is also a potential contributor to increased aortic wall proinflammation and stiffness that accompanies advancing age. Indeed, serum MFG-E8 levels correlate with levels of inflammatory molecules MCP-1 and TNF-α and with pulse wave velocity (PWV), an index of arterial stiffening in old humans [74].

Central Arterial Aging and Ang II Signaling
A growing body of evidence indicates that changes in Ang II and its downstream signaling significantly affect age-associated central arterial remodeling. Increased activation of the renin–angiotensin–aldosterone system and an increase in oxidative stress are both implicated in age-related arterial remodeling, contributing to arterial proinflammation. The proinflammation within cells and ECM of the arterial wall consequently facilitate adverse arterial restructuring via alterations of arterial cells and ECM with advancing age (fig. 1). Chronic infusion of a physiologic relevant dose of Ang II to young rats (8-month-old) increases expression of molecular activity that comprise the proinflammation profile, e.g. MMP-2, MCP-1, calpain-1, TGF-β1, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) and elicits the age-associated increase in arterial and coronary structural manifestations of old (30-month-old), untreated arteries, i.e. intimal and media thickening [18, 41]. In addition, the α-adrenoreceptor agonist, phenylephrine, increases arterial Ang II protein, causing MMP-2 activation and intimal and medial thickening [18].

Interventions of Arterial Aging

Blockade of Ang II Signaling
Ang II signaling plays a causal role in the process of arterial aging. Interestingly, chronic angiotensin-converting enzyme1 (ACE-1) inhibition and AT1 receptor blockade, beginning at an early age, markedly inhibit the expression of proinflammatory molecules, reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin, and delays the progression of age-associated aortic remodeling such as elastin fragmentation and collagen deposition [75–77].

Blockade of MMPs
Age-associated arterial remodeling, due to arterial wall collagen deposition and elastin fragmentation, are associated with an increase in arterial blood pressure (BP). Chronic administration of a broad-spectrum MMP inhibitor, PD166793, markedly blunts the age-associated increases in aortic gelatinase and interstitial collagenase activity, and reduces the elastic fiber degeneration, collagen deposition, MCP-1 expression, TGF-β1 activation, and SMAD-2/3 phosphorylation [45]. Interestingly, MMP inhibition also substantially diminishes pro-ET-1 activation and downregulates Ets-1 expression [45]. Importantly, MMP inhibition substantially retards the age-associated increase in BP [45].

Breakdown of AGEs
AGEs are a major determinant of arterial stiffening with aging. Administration of ALT-711 (3-phenacyl-4,5-dimethylthiazolium chloride), a non-enzymatic cross-link breaker of AGEs, for 39 weeks improved arterial compliance and ventricular function and optimized ventriculo-vascular coupling in older non-human primates [78]. Moreover, ALT-711 treatment for 56 days significantly improved total arterial compliance and lower pulse pressure in older humans with vascular stiffening [79]. Thus, increased collagen cross-linking via glycoxidation is an important molecular event of age-associated arterial stiffening.

Calorie Restriction and SIRT1 Activity
Calorie restriction (CR) is a dietary approach to improve health and slow the aging process in both experimental animals and humans. The expression of SIRT1, a longevity gene, decreases with aging within the arterial wall, contributing to arterial proinflammation, endothelial dysfunction, and stiffening [7]. Interestingly, CR retards EC apoptosis/senescence aging features and increases lifespan in rodents, which is closely associated with an increase in SIRT1 activity [80]. Resveratrol, an activator of SIRT1, mimics CR, retarding arterial wall adverse remodeling and lipid deposition in the perivascular space of the heart in rodents fed a high-fat diet via increase of insulin sensitivity and mitochondria function [81]. Impressively, the AAASP in monkey VSMCs is substantially reversed by resveratrol [28]. Importantly, overexpression of SIRT1 inhibits both VSMC AT1 expression and NADPH oxidase activation and blunts Ang II-induced hypertension [82]. These findings suggest that CR/resveratrol treatment retards aging likely via an inhibition of Ang II-driven oxidation.

Physical Conditioning and Blockade of Proinflammation
It is known in humans that habitual physical activity leads to improvement in arterial structure and function with aging by increasing resistance to the effects of car-
diovascular risk factors like oxLDL cholesterol [61, 62, 83]. Several studies in both aging rodents and humans have demonstrated that vascular endothelial dysfunction and stiffening are improved with voluntary aerobic exercise through a pronounced reduction of the inflammation markers TNF-α, NF-κB, NADPH oxidase, and TGF-β1, as well as an enhancement of NO bioavailability and Nrf2 activity [61, 62, 83].

**Concluding Remarks**

Arterial aging is a journey into subclinical adverse arterial remodeling. Disruption of the endothelium, and augmented VSMC migration/proliferation/senescence, ECM deposition, elastin fracture, and matrix glycooxidative modifications, are characteristics of the arterial aging phenotype. These adverse cellular events are recapitulated in experimental young animals in response to chronic Ang II infusion, and are attenuated in old animals via interference of proinflammatory signaling in vivo. Since the age-associated molecular and cellular events set a stage for the pathogenesis of hypertension and atherosclerosis, interventions of arterial proinflammation with aging may effectively curb the epidemic of cardiovascular disease in the elderly.

**Acknowledgement**

This research was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health.

**Disclosure Statement**

The authors have no conflicts of interest to disclose.

**References**


2. Wang M, Jiang L, Monticone RE, Lakatta EG: TGF-β1, as well as an enhancement of NO bioavailability cise through a pronounced reduction of the inflammation markers TNF-α, NF-κB, NADPH oxidase, and TGF-β1, as well as an enhancement of NO bioavailability. Artery Res 2013;7:73–80.


Proinflammation of Aging Central Arteries

Gerontology 2014;60:519–529
DOI: 10.1159/000362548


